Holen Sie sich die Stockscreener-App
1.27
12.89%
0.145
Handel nachbörslich:
1.27
Reviva Pharmaceuticals Holdings Inc Aktie (RVPH) Neueste Nachrichten
ARMISTICE CAPITAL, LLC Acquires New Stake in Reviva Pharmaceuticals Holdings Inc - GuruFocus.com
Schonfeld Strategic Advisors LLC Increases Stake in Reviva Pharm - GuruFocus.com
Reviva Pharmaceuticals Holdings Inc. Warrants (RVPHW) Quarterly 10-Q Report - Quartzy
Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewswire
Reviva Pharma: 108 Patients Complete 1-Year Schizophrenia Drug Trial as Losses Narrow | RVPH Stock News - StockTitan
Reviva reports progress in schizophrenia treatment study By Investing.com - Investing.com Australia
Reviva reports progress in schizophrenia treatment study - Investing.com
Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia - GlobeNewswire
Reviva's Brilaroxazine Hits Key Milestone: 108 Patients Complete 1-Year Schizophrenia Trial | RVPH Stock News - StockTitan
Reviva to Present Positive Speech Latency Data for - GlobeNewswire
Reviva Pharma to Present Breakthrough Phase 3 Schizophrenia Drug Data at CNS Summit | RVPH Stock News - StockTitan
Reviva to Participate in the UBS Global Healthcare Conference - GlobeNewswire
Reviva To Report Long-Term Safety Data For Brilaroxazine In Schizophrenia: Will The Stock Recover? - RTTNews
Schizophrenia Clinical Trial Pipeline Insights Featuring 55+ Companies | DelveInsight - GlobeNewswire Inc.
Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit - The Manila Times
Reviva Pharmaceuticals Schizophrenia Drug Demonstrates Strong Efficacy On Heels Of Bristol Myers, FDA Approval: Analyst - Benzinga
Reviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference - GlobeNewswire
Reviva Pharmaceuticals to Participate in the Lytham Partners Fall 2024 Investor Conference - The Manila Times
CA Pharma Co. Reports Positive Phase 3 Data for Schizophrenia Treatment - Streetwise Reports
RVPH’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle
Market Momentum: Reviva Pharmaceuticals Holdings Inc. (RVPH) Registers a 9.40 Increase, Closing at 1.28 - The Dwinnex
RVPH: RECOVER Biomarker KOL Event - Yahoo Finance
Closing Strong: Reviva Pharmaceuticals Holdings Inc. (RVPH) Ends at 1.12, Down -13.85 from Last Close - The Dwinnex
A stock that deserves closer examination: Reviva Pharmaceuticals Holdings Inc. (RVPH) - US Post News
Reviva reports positive schizophrenia trial results - Investing.com India
Reviva Announces New Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia - GlobeNewswire
How to interpret Reviva Pharmaceuticals Holdings Inc. (RVPH)’s stock chart patterns - US Post News
Reviva Pharmaceuticals Holdings Inc. (RVPH) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Reviva to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
RVPH’s Stock Market Adventure: -79.42% YTD Growth Amidst Volatility - The InvestChronicle
Reviva to Host Virtual KOL Event to Discuss Vocal Biomarker - GlobeNewswire
Reviva to Host Virtual KOL Event to Discuss Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia on September 4, 2024 - StockTitan
RVPH: August OLE Update - Yahoo Finance
Reviva Pharmaceuticals Launches Multi-Million Share Offering - TipRanks
Reviva Pharmaceuticals Holdings Inc. (NASDAQ: RVPH) Drops -25.71% In Early Trade; What Lies Ahead? - Stocks Register
Reviva Pharmaceuticals Holdings Inc. [RVPH] stock Initiated by ROTH MKM analyst, price target now $12 - The DBT News
Check Out Reviva Pharmaceuticals Holdings Inc. (RVPH)’s Trade Data Rather Than the Analysts’ Views - SETE News
Reviva Pharmaceuticals Announces Pricing of $5.0 Million - GlobeNewswire
Reviva Pharmaceuticals Announces Pricing of $5.0 Million Underwritten Offering Priced At-the-Market Under Nasdaq Rules - Marketscreener.com
A closer look at Reviva Pharmaceuticals Holdings Inc. (RVPH) is warranted - US Post News
Reviva Pharmaceuticals Holdings Inc.’s Shares Reel: -62.34% Quarterly Revenue Decline Amid 19.20M Market Cap - The InvestChronicle
Ratios Reveal: Breaking Down Reviva Pharmaceuticals Holdings Inc. (RVPH)’s Financial Health - The Dwinnex
Vanguard Group Inc. Purchases 26,854 Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) - Defense World
Reviva Pharmaceuticals (NASDAQ:RVPH) Stock Rating Reaffirmed by Maxim Group - Defense World
Maxim Group Downgrades Reviva Pharmaceuticals Holdings (RVPH) - MSN
Reviva Pharmaceuticals Holdings Inc. Inc. (RVPH) Price Performance Over the Years: A Comparative Study - The InvestChronicle
Reviva Reports Second Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewswire
Balance Sheet Insights: Reviva Pharmaceuticals Holdings Inc. (RVPH)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
RVPH stock touches 52-week low at $0.76 amid market challenges - Investing.com
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):